Johnson & Johnson Vision, the American Optometric Association, the Singapore Optometric Association, and the American Academy of Optometry have partnered to create Managing Myopia: A Clinical Response to the Growing Epidemic, a guide to support eye care professionals in managing myopia in patients, launching in two 1-hour live stream events.
Intended to provide guidance to eye care practitioners in the management of myopia in clinical practice, this guide has been created in collaboration with the American Optometric Association, the Singapore Optometric Association, the American Academy of Optometry, and Johnson & Johnson Vision and is informed by currently available scientific research.
The rate of myopia prevalence has doubled over the past 20 years, and by 2050 half of the world's population is projected to be myopic.1 So how can we slow its progression? Johnson & Johnson Vision is collaboratively advancing the next generation of science, researching and developing new solutions with the potential to transform the standards of care in myopia, and changing the trajectory of eye health.
We are proud to partner with these distinguished individuals to help educate eye care professionals about myopia, the greatest eye health threat of the 21st century.
Myopia is a chronic, progressive disease characterized by excessive eye elongation, risk of associated sight-threatening complications, and a negative-powered refractive error.
Reports of increased myopia prevalence in Taiwan, Singapore, and Hong Kong emerged in the 1980s, and rates have continued to rise worldwide4. Those in the first wave of increased prevalence are on the cusp of experiencing sight-threatening complications.
There is no safe level of myopia5. From an early age, measuring and monitoring both axial length and refractive error is highly recommended in all myopic children with even moderate risk of myopia progression.
Measurement of axial length is the preferred method for monitoring myopia progression over refractive error because of the strong association between eye length and risk of developing complications. Treatment efficacy should be measured with Cumulative Absolute Reduction in axial Elongation (CARE)6.